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Abstract
Background: High body temperatures after ischemic stroke have been associated with larger infarct size, but the
temporal profile of this relation is unknown. We assess the relation between temporal profile of body temperature
and infarct size and functional outcome in patients with acute ischemic stroke.
Methods: In 419 patients with acute ischemic stroke we assessed the relation between body temperature on
admission and during the first 3 days with both infarct size and functional outcome. Infarct size was measured
in milliliters on CT or MRI after 3 days. Poor functional outcome was defined as a modified Rankin Scale score
≥3 at 3 months.
Results: Body temperature on admission was not associated with infarct size or poor outcome in adjusted
analyses. By contrast, each additional 1.0 °C in body temperature on day 1 was associated with 0.31 ml larger
infarct size (95% confidence interval (CI) 0.04–0.59), on day 2 with 1.13 ml larger infarct size(95% CI, 0.83–1.43),
and on day 3 with 0.80 ml larger infarct size (95% CI, 0.48–1.12), in adjusted linear regression analyses. Higher
peak body temperatures on days two and three were also associated with poor outcome (adjusted relative
risks per additional 1.0 °C in body temperature, 1.52 (95% CI, 1.17–1.99) and 1.47 (95% CI, 1.22–1.77),
respectively).
Conclusions: Higher peak body temperatures during the first days after ischemic stroke, rather than on admission, are
associated with larger infarct size and poor functional outcome. This suggests that prevention of high temperatures
may improve outcome if continued for at least 3 days.
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Background
Acute ischemic stroke is a devastating disease, leaving
more than half of patients with a poor functional outcome
[1]. High body temperatures in the early stage after ische-
mic stroke have consistently been associated with poor
functional outcome [2–13]. Preclinical studies suggest that
hyperthermia increases metabolic demands, release of
neurotransmitters, free-radical production and breakdown
of the blood–brain barrier after cerebral ischemia, hereby
increasing cell death and infarct volume [14].
The association between body temperature and infarct
size in patients with ischemic stroke is however still
controversial, mainly when it comes to the temporal
profile of this association. Two studies did not find a
relation with body temperatures on admission [4] or
after 6–12 h [15]. One study did show an association
between infarct size and body temperature on admission,
[11] and two between infarct size and body temperature
at 24 h [3, 6]. Temperature assessment in all studies was
limited to the first 24 h after stroke onset.
The temporal profile of the association between body
temperature and functional outcome or death also show
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inconsistent results. Several studies have suggested that
this is limited to body temperatures on admission or
during the first day, [3, 5, 6, 10, 11, 13] whereas others
have found that this relation persists for up to one week
[2, 7–9, 12]. These inconsistencies may be attributed to
differences in study designs and populations, [8] for
example related to the time of admission, [13] the
definition of a poor outcome outcome, [11] and selec-
tion of patient populations [3, 10].
In this study, we assessed the temporal profile of the
relation between body temperatures during the first
three days after ischemic stroke and infarct size and
functional outcome.
Methods
This is a substudy of the Dutch acute STroke study
(DUST). Patients older than 18 years were included
between May 2009 and August 2013 if they had
symptoms suspected to be caused by ischemic stroke.
Inclusion criteria were symptom duration <9 h, and
National Institutes of Health Stroke Scale (NIHSS) ≥2,
or ≥1 if intravenous thrombolysis with recombinant
tissue type plasminogen activator (IV-rtPA) was indi-
cated. Patients were not eligible if another diagnosis
on non contrast CT (NCCT) such as intracranial
hemorrhage explained the symptoms. Patients with an
unknown onset time were included if the elapsed time
between the time they were last seen without symp-
toms and imaging was <9 h [16].
We selected patients enrolled at the five of 14 DUST
study centers that had included over 100 patients.
Tympanic or rectal temperatures over the first 72 h after
stroke onset were retrospectively collected from patients’
charts by one single investigator (FEVS), who was blinded
for outcome measures. For each patient, we recorded the
mean body temperature and the peak body temperature
(highest body temperature) on days one to three after
admission. Body temperature on admission was defined as
the first recorded body temperature within six hours after
admission; day one as the first 24 h after stoke onset, day
two as 24 to 48 h, and day three as 48 to 72 h after stroke
onset. Patients were included if at least one body
temperature was recorded.
Infarct size was measured three (± two) days after
symptom onset. The default follow-up imaging modality
was non contrast CT (NCCT) after 3 days or at the time
of clinical deterioration or earlier discharge. Follow-up
MRI was used if this had been performed for clinical
reasons instead of NCCT. Infarct volume was obtained
by manually delineating the hypodense infarcted area(s)
on axial NCCT slices and hyper-intense area(s) on axial
DWI slices on MRI. The surface of these area(s) was
subsequently multiplied by the slice thickness to obtain
the infarct volume [16]. Patients with no visible infarct
on follow-up scan were included in the analyses with an
infarct volume of 0 ml. Functional outcome was mea-
sured with the modified Rankin Scale (mRS) at 90 days
by a trained research nurse or neurologist. Poor out-
come was defined as mRS ≥3.
The primary outcome measure was infarct volume (ml)
at 3 days. The relation between each additional 1.0 °C in
body temperature and infarct size was calculated by
means of linear regression, and the relation between body
temperatures and functional outcome with Poisson
regression analysis with a robust error. The relation was
expressed as regression coefficient (B) or relative risk (RR)
with corresponding 95% confidence interval (CI), re-
spectively. We adjusted for age, sex, previous stroke,
hypertension, diabetes mellitus, current smoking, treat-
ment with intravenous alteplase, intra-arterial treatment,
and National Institutes of Health Stroke Scale (NIHSS)
score on admission, with backward stepwise regression
with 0.10 alpha levels of removal. Potential confounders
were selected on basis of known associations with the out-
come. We considered a p-value ≤0.05 significant.
Results
Of 1393 patients included in DUST, 696 were included
in the five selected centers. We included 419 of these pa-
tients for the present study, after excluding 173 patients
without follow-up imaging, 66 without a recorded body
temperature available and 38 with an other diagnosis
than ischemic stroke (Fig. 1).
The mean age of the patients was 66 years (SD 13);
256 (61%) were male. Additional patient characteristics
are presented in Table 1. Follow-up imaging was per-
formed with CT (95%) or MRI (5%). Patients without
follow-up imaging were older (70 vs 66 years, p = 0.001),
were more often men, and had a higher median NIHSS
score on admission (7 vs 6, p = 0.02; Table 1).
At follow-up, median infarct volume was 1.5 ml
(range, 0–500 ml) in the total study population of 419
patients. There were 131 (31%) patients without a visible
infarct on follow up imaging, i.e. an infarct volume of
0 ml. The mean body temperatures during the first 3
days are presented in Fig. 2.
A total number of 406 patients had at least one body
temperature recorded at day one, 376 patients at day
two, and 308 patients at day three. The mean peak body
temperature on day one was 37.3 °C (SD 0.8), on day
two 37.3 °C (SD 0.6), and on day three 37.1 °C (SD 0.5;
Fig. 1). Mean and peak body temperatures were higher
at days one, two and three than on admission (p < 0.001
for all days).
Higher peak body temperatures on days one, two and
three after stroke onset were associated with larger
infarct size. In adjusted linear regression analyses, each
additional 1.0 °C in body temperature on day 1 was
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associated with 0.31 ml larger infarct size (95% CI, 0.04–
0.59), on day 2 with 1.13 ml larger infarct size (95% CI,
0.83–1.43), and on day 3 with 0.80 ml larger infarct size
(95% CI, 0.48–1.12) (Fig. 3, Table 2). Peak body tempera-
tures on days two and three were also associated with a
poor outcome (Fig. 4, Table 2). With every additional
1.0 °C in peak body temperature on days two and three,
the risk of a poor outcome was 52% (95% CI, 17–99%)
and 47% (95% CI, 22–77%) larger, respectively. Body
temperature on admission was neither related to infarct
size nor to functional outcome. Mean body tempera-
tures at days one, two and three were, after adjustment,
neither associated with infarct size nor with poor func-
tional outcome.
Subgroup analyses
In a post-hoc subgroup analysis of 288 patients with
a visible infarct on follow-up imaging, median infarct
volume was 9.6 ml (range, 0.2–500). Results were
essentially the same (Table 3). In a post-hoc subgroup
analysis of 398 patients with CT as follow-up imaging
modality, results were essentially the same (data not
shown).
Discussion
This study shows that in patients with acute ischemic
stroke, higher peak body temperatures on days one, two
and three after stroke onset are associated with larger in-
farct size. Peak body temperatures on days two and three
were also associated with poor functional outcome after
3 months. Body temperature at admission was neither
related to infarct size nor to functional outcome.
This is the first study that assesses the temporal profile
of the association between body temperature and infarct
size in the first days after stroke.
Fig. 1 Flow of patients through this study
Table 1 Patient characteristics
Included
patients
(n = 419)
Patients without
follow-up imaging
(n = 173)
p-value
Age (years) 66 (13) 70 (15) 0.001
Men 256 (61) 84 (49) 0.01
Body temperature
on admission (°C)
36.7 (0.6) 36.7 (0.8) 0.94
NIHSS on admission 6 (10) 7 (10) 0.02
Hypertension 206 (49) 102 (59) 0.25
Diabetes mellitus 65 (16) 23 (13) 0.49
Current smoking 122 (29) 38 (22) 0.39
Previous stroke 88 (21) 43 (25) 0.38
TOAST 0.66
Large-artery
atherosclerosis
130 (31) 51 (30)
Cardioembolism 79 (19) 33 (19)
Small vessel
disease
49 (12) 16 (9)
Other 24 (6) 4 (9)
Unknown 137 (32) 58 (33)
Posterior circulation
stroke
14 (3) 2 (3) 0.67
Treatment with
intravenous alteplase
249 (59) 112 (65) 0.29
Intra-arterial
treatment
26 (6) 11 (6) 0.94
Poor outcome
(mRS ≥3)
144 (34) 71 (41) 0.11
Data are n (%), median (range), median (interquartile range (IQR)) or mean
(standard deviation (SD)) where appropriate. NIHSS, National Institutes of
Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment
classification; mRS, modified Rankin Scale
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High body temperature after stroke may be the result of
infections, which are frequent and have also been associ-
ated with poor functional outcome. However, no source of
infection could be found in almost half of the hyperther-
mic patients in a previous study [8]. Fever could also be
the result of an inflammatory response of the body to the
infarcted tissue. Additionally, in the first days after stroke
temperature-dependent processes which lead to increased
extracellular edema, infarct swelling, and restricted
capillary flow in the ischemic tissue, can increase ische-
mic damage [8]. Although increased body temperature
is often thought to be a reflection of extensive cerebral
damage, we found an association between increased
body temperature and poor functional outcome that
was independent of baseline stroke severity.
If the relation between higher body temperatures and
larger infarct volumes and poor functional outcome is at
least partially causal, our findings suggest that a reduc-
tion in body temperature up to 3 days after stroke may
reduce infarct size and improve functional outcome. In a
post-hoc subgroup analysis of the randomized Paraceta-
mol (Acetaminophen) In Stroke (PAIS) trial, treatment
with paracetamol for 3 days was associated with an
improvement in functional outcome at 3 months in
patients with a baseline body temperature of 37.0 °C or
above, [17] supporting the causal relationship between
body temperature and functional outcome.
Our study has limitations. First, we had to exclude 173
patients because of lack of follow-up scans, and of the
remaining patients we excluded 10% without any
Fig. 2 Course of body temperatures in the first 3 days after stroke onset
Fig. 3 Relation between infarct size and peak body temperature
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recorded temperature. Up to 27% of included patients
did not have temperature measurements on one of the 3
days. We used tympanic and rectal temperatures inter-
changeably, whereas values may differ between those
methods. In addition, patients in our study may have
been treated with antipyretics, which could have affected
temperature measurements and would underestimate
the number of patients with high body temperatures.
However, by assessing the peak body temperatures
rather than mean temperatures, we aimed to assess body
temperatures before administration of antipyretics. This
may also explain our finding that mean body tempera-
tures were not related to infarct size or functional out-
comes. Of the included patients, one third had no visible
infarct on follow-up CT. One could argue that these
patients did not suffer from cerebral ischemia. However,
in subgroup analysis including patients with a visible
infarct results were essentially the same. We included
patients without a visible infarct on follow-up imaging in
this substudy to ensure the association we assess applies
to all patients with the clinical diagnosis of stroke,
including the small strokes and patients that recover
completely. Infarct size was measured on either CT or
MRI. As the default follow-up modality was CT, it is
possible that some smaller infarcts were not detected.
However, in subgroup analysis including only patients
with CT as follow-up modality, results were essentially
the same.
With a median NIHSS of 6 on admission, included
patients had relatively milder strokes than excluded patients
(median NIHSS of 7). Our data may differ in a selection of
patients with severe stroke. The time between stroke onset
and first measurement of temperature was not predefined
in the DUST study protocol. Therefore, the variation
between time from stroke onset to first recorded body
temperature might have affected our results. We did not
have data on the occurrence of infections in our population
and could therefore not analyze their relationship with
Table 2 The relation between body temperature and infarct size
Infarct size at day 3 (±2) Functional outcome at 90 days
After adjustmenta After adjustmenta
B 95%CI P RR 95%CI P
Body temperature on admission n = 333 −0.15 −0.49–0.18 0.38 0.99 0.77–1.26 0.90
Peak body temperature on day 1 n = 404 0.31 0.04–0.59 0.02 1.20 0.99–1.46 0.06
Mean body temperature on day 1 n = 404 0.09 −0.41–0.60 0.71 1.38 0.84–2.28 0.21
Peak body temperature on day 2 n = 375 1.13 0.83–1.43 <0.001 1.52 1.17–1.99 0.002
Mean body temperature on day 2 n = 375 −0.27 −0.78–0.26 0.33 0.74 0.33–1.64 0.46
Peak body temperature on day 3 n = 306 0.80 0.48–1.12 <0.001 1.47 1.22–1.77 <0.001
Mean body temperature on day 3 n = 306 0.40 −0.18–0.97 0.17 1.64 0.83–3.25 0.16
B, regression coefficient in ml per additional 1.0 °C in body temperature; CI, confidence interval
aAdjusted for age, sex, previous stroke, hypertension, diabetes mellitus, current smoking, treatment with intravenous alteplase, intra-arterial treatment and National
Institutes of Health Stroke Scale score on admission
Fig. 4 Relation between poor functional outcome and peak body temperature
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hyperthermia. We present results per 1.0 °C, which results
in wide confidence intervals.
As a result of small patient numbers in extreme body
temperature categories, this study is insufficient to
detect associations at body temperatures lower than
35.5 °C or higher than 38.5 °C.
Conclusions
In conclusion, we found that higher body tempera-
tures in the first days after ischemic stroke, rather
than on admission, are associated with larger infarct
size and poor functional outcome. Our findings sug-
gest that prevention of high temperatures in clinical
trials may improve outcome if continued for at least
three days.
Guidelines recommend the use of antipyretics for
febrile patients with stroke, but do not provide a time
window [18]. In the randomised Paracetamol (Acet-
aminophen) In Stroke (PAIS) trial, treatment of patients
with a baseline body temperature of 37 °C or above
with high-dose paracetamol, started within 12 h of
stroke onset and continued for 3 days, resulted in a
temperature reduction of just 0.3 °C at 24 h, but also in
an improved outcome at 3 months [17]. A large phase
III trial on the effect of induced hypothermia after
stroke is ongoing, cooling patients 12 to 24 h after their
stroke [19]. Future clinical trials should further assess
the effect of preventing fever or inducing hypothermia
up to at least 3 days after stroke.
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Table 3 Relation between body temperature and infarct size in patients with an infarct of >0 ml
Infarct size at day 3 (±2) Functional outcome at 90 days
After adjustmenta After adjustmenta
B 95%CI P RR 95%CI P
Body temperature on admission n = 202 0.04 −0.32–0.40 0.83 1.10 0.83–1.48 0.53
Peak body temperature on day 1 n = 273 0.26 −0.04–0.57 0.09 1.19 0.95–1.48 0.13
Mean body temperature on day 1 n = 273 0.28 −0.43–0.99 0.44 1.23 0.50–3.03 0.65
Peak body temperature on day 2 n = 244 0.87 0.53–1.22 <0.001 1.43 1.07–1.91 0.02
Mean body temperature on day 2 n = 244 0.06 −0.59–0.72 0.85 0.64 0.27–1.05 0.31
Peak body temperature on day 3 n = 175 0.62 0.27–0.97 0.001 1.45 1.14–1.84 0.002
Mean body temperature on day 3 n = 175 0.90 0.22–1.60 0.01 1.49 0.73–3.10 0.28
B, regression coefficient in ml per additional 1.0 °C in body temperature; CI, confidence interval
aAdjusted for age, sex, previous stroke, hypertension, diabetes mellitus, current smoking, treatment with intravenous alteplase, intra-arterial treatment and National
Institutes of Health Stroke Scale score on admission
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